BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND ATP2B3, PMCA3, 492, ENSG00000067842 AND Treatment
23 results:

  • 1. [Clinicopathologic features and prognosis of young renal tumors with tumor thrombus].
    Xue ZX; Tang SY; Qiu M; Liu C; Tian XJ; Lu M; Dong JH; Ma LL; Zhang SD
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):802-811. PubMed ID: 37807732
    [TBL] [Abstract] [Full Text] [Related]  

  • 2.
    Situ Y; Zhang J; Liao W; Liang Q; Lu L; Xu Q; Chen J; Lu X; Cui Y; Shao Z; Deng L
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):196. PubMed ID: 37796681
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
    Kobayashi M; Numakura K; Hatakeyama S; Ishida T; Koizumi A; Tadachi K; Igarashi R; Takayama K; Muto Y; Sekine Y; Sobu R; Sasagawa H; Akashi H; Kashima S; Yamamoto R; Nara T; Saito M; Narita S; Ohyama C; Habuchi T
    Int J Clin Oncol; 2023 Nov; 28(11):1530-1537. PubMed ID: 37552353
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Development of an Immune Prognostic Model for Clear Cell Renal Cell Carcinoma Based on Tumor Microenvironment.
    Wang M; Song Q; Song Z; Xie Y
    Horm Metab Res; 2023 Jun; 55(6):402-412. PubMed ID: 37192644
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
    Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Using machine learning to predict lymph node metastasis in patients with renal cell carcinoma: A population-based study.
    Zhang Y; Yi X; Tang Z; Xie P; Yin N; Deng Q; Zhu L; Luo H; Peng K
    Front Public Health; 2023; 11():1104931. PubMed ID: 37033061
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Adoption of Innovative Therapies Across Oncology Practices-Evidence From Immunotherapy.
    Carroll CE; Landrum MB; Wright AA; Keating NL
    JAMA Oncol; 2023 Mar; 9(3):324-333. PubMed ID: 36602811
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection.
    Sun F; Li Z; Hu L; Deng W; Jiang T; Wang S; Bi X; Lu H; Yang L; Lin Y; Zeng Z; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Zhang L; Lu Y; Dong J; Xie Y; Li M
    Front Immunol; 2022; 13():1082091. PubMed ID: 36505492
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
    Aeppli S; Engeler DS; Fischer S; Omlin A; Pratsinis M; Hermann C; Rothermundt C
    Swiss Med Wkly; 2022 Jun; 152():w30175. PubMed ID: 35752957
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. System analysis of
    Situ Y; Xu Q; Deng L; Zhu Y; Gao R; Lei L; Shao Z
    Int J Biol Markers; 2022 Mar; 37(1):90-101. PubMed ID: 34870494
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
    Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S
    Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Circular RNA circ_0001368 inhibited growth and invasion in renal cell carcinoma by sponging miR-492 and targeting LATS2.
    Chen L; Wu D; Ding T
    Gene; 2020 Aug; 753():144781. PubMed ID: 32428698
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy.
    Mori K; Janisch F; Mostafaei H; Kimura S; Lysenko I; Karakiewicz PI; Briganti A; Enikeev DV; Rouprêt M; Margulis V; Chlosta P; Nyirady P; Babjuk M; Egawa S; Shariat SF
    Urol Oncol; 2020 Jun; 38(6):601.e17-601.e24. PubMed ID: 32127252
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
    Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival.
    Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J
    Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Relationship Between Mortality and Cancer-Bearing Status at Time of Dialysis Initiation.
    Tanaka A; Inaguma D; Shinjo H; Murata M; Takeda A
    Ther Apher Dial; 2017 Aug; 21(4):345-353. PubMed ID: 28322029
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Upregulation of microRNA-492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro.
    Wu A; Wu K; Li M; Bao L; Shen X; Li S; Li J; Yang Z
    Mol Med Rep; 2015 Jul; 12(1):1413-20. PubMed ID: 25815441
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha.
    Yang S; de Souza P; Alemao E; Purvis J
    Br J Cancer; 2010 May; 102(10):1456-60. PubMed ID: 20461090
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma.
    Brookman-Amissah S; Kendel F; Spivak I; Pflanz S; Roigas J; Klotz T; May M
    BJU Int; 2009 May; 103(10):1375-80. PubMed ID: 19040527
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.